Return to search results.
Complete title: A randomized, prospective, double blind, placebocontrolled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors
|Research Study Number||2523.00|
|Principal Investigator||Paul Martin, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Lymphoproliferative Disease; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.